From professional translators, enterprises, web pages and freely available translation repositories.
ledipasvir:
(200 mg/300 mg q.d.)1
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
↓ ledipasvir
↓ sofosbuvir
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
harvoni ledipasvir / sofosbuvir
harvoni ledipasvirum/sofosbuvirum
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
ledipasvir activity (ec50, nm)
aktivita ledipasviru (ec50, nm)
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
use with ledipasvir and sofosbuvir
použití s ledipasvirem a sofosbuvirem
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
ledipasvir solubility decreases as ph increases.
se stoupající hodnotou ph klesá rozpustnost ledipasviru.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
the active substances are ledipasvir and sofosbuvir.
léčivými látkami jsou ledipasvirum a sofosbuvirum.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
see also under use with ledipasvir and sofosbuvir below.
přečtěte si také část použití s ledipasvirem a sofosbuviren níže.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
harvoni contains the active substances ledipasvir and sofosbuvir.
přípravek harvoni obsahuje léčivé látky ledipasvir a sofosbuvir.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
1 data generated from simultaneous dosing with ledipasvir/sofosbuvir.
1 Údaje získané souběžným podáváním ledipasviru/sofosbuviru.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
ledipasvir/sofosbuvir (90 mg/400 mg q.d.) +
(90 mg/400 mg q.d.) +
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
ledipasvir auc is dose proportional over the dose range of 3 to 100 mg.
hodnota auc ledipasviru je přímo úměrná dávce v rozsahu dávek od 3 do 100 mg.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
ledipasvir is > 99.8% bound to human plasma proteins.
ledipasvir je z > 99,8 % navázán na proteiny lidské plazmy.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Warning: Contains invisible HTML formatting
each film-coated tablet contains 90 mg ledipasvir and 400 mg sofosbuvir.
jedna potahovaná tableta obsahuje ledipasvirum 90 mg a sofosbuvirum 400 mg.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
in vitro potential for ledipasvir/sofosbuvir to affect other medicinal products
možnost ovlivnění jiných léčivých přípravků ledipasvirem/sofosbuvirem in vitro
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
animal studies do not indicate harmful effects of ledipasvir or sofosbuvir on fertility.
studie na zvířatech nenaznačují škodlivé účinky ledipasviru nebo sofosbuviru na fertilitu.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
these studies did not include any control group not receiving ledipasvir/sofosbuvir.
tyto studie nezahrnovaly kontrolní skupinu, která neužívala ledipasvir/sofosbuvir.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
biochemical confirmation of ns5a inhibition by ledipasvir is not currently possible as ns5a has no enzymatic function.
biochemické ověření inhibice ns5a ledipasvirem není v současné době možné, protože ns5a nemá enzymatickou funkci.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
the exposures to gs-331007 and ledipasvir were not altered in the presence of either meal type.
expozice gs-331007 a ledipasviru nebyly přítomností jídla žádného typu ovlivněny.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
all three phase 3 studies evaluated the efficacy of ledipasvir/sofosbuvir with or without ribavirin.
všechny tři studie fáze 3 hodnotily účinnost ledipasviru/sofosbuviru s ribavirinem nebo bez něho.
Last Update: 2017-04-26
Usage Frequency: 1
Quality: